Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
141.20 86.43 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Piotroski F-Score
4 5 4 8 — — — 4 4 2
Altman Z-Score
16.83 23.76 25.08 26.41 (13.25) (1.65) — 8.65 (3.81) (6.50)
P/S ratio
5.41 9.74 13.80 5.26 3.80 5.78 — 117.56 48.36 19.35
P/FCF ratio
0.00 0.00 87.15 98.87 0.00 0.00 — 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
8.71 5.15 (2.01) 9.96 (26.84) (5.67) — 24.45 (9.29) (12.82)
P/Operating CF
(112.14) (373.33) 466.11 13.30 (1.58) (5.48) — (9.82) (7.79) (1.55)
Beneish M-Score
(2.02) (1.20) (6.80) 9.51 — — — — — (3.91)
P/B ratio
10.59 10.46 112.28 7.79 0.68 1.59 — 0.74 1.60 0.48
Price to Tangible BV
11.51 10.65 127.84 8.00 0.68 1.59 — 0.74 1.60 0.48
EV/Sales
4.66 9.53 13.56 5.07 (1.87) 2.24 — (35.09) 16.39 (23.22)
EV/EBITDA
38.79 56.80 0.00 52.54 0.16 0.00 — 0.78 0.00 0.46
EV/Operating CF
537.99 (276.90) 59.40 50.84 0.16 (0.85) — 0.93 (0.84) 0.50
EV/FCF
(615.37) (158.25) 85.58 95.36 0.16 (0.85) — 0.91 (0.84) 0.57
Quick Ratio
4.58 2.64 2.49 3.46 3.44 4.65 3.18 25.03 4.32 1.66
Current Ratio
5.60 3.32 2.85 4.06 3.63 5.03 3.32 25.83 4.48 1.71
Net Debt/EBITDA
(3.74) (1.50) 0.51 (2.44) 0.53 1.39 1.35 3.57 1.51 0.86
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.87% 50.94%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 1.21
Asset Turnover
0.80 0.87 1.13 1.46 0.10 0.22 0.00 0.00 0.03 0.01
Operating CF/Net income
0.20 (0.30) (0.28) 4.64 0.95 0.98 0.79 0.95 0.78 1.09
Capex/Depreciation
(0.75) (1.72) (7.11) (4.43) (2.89) (1.93) (0.44) (2.52) (0.13) 5.39
Interest Coverage
— — — 17.14 (2,253.69) (102.26) (26.70) — — —
ROE
4.18% 21.51% (215.71%) 4.06% (150.11%) (77.89%) (58.61%) (39.88%) (108.92%) (71.35%)
ROA
3.45% 9.99% (92.34%) 3.28% (116.85%) (58.16%) (49.38%) (36.56%) (65.75%) (31.49%)
ROIC
7.99% 14.08% (93.45%) 12.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
4.67% 17.48% (153.70%) 4.18% (229.70%) (77.95%) (81.78%) (25.13%) (83.25%) (105.91%)
Average Days of Receivables
98.02 85.52 52.92 61.15 90.43 57.73 0.00 0.00 0.00 28.36
Research and Development Expense of Revenue
11.75% 11.37% 85.40% 16.31% 938.80% 252.89% 0.00% 357,900.00% 1,261.98% 2,895.99%
Selling, General and Administrative Expense of Revenue
73.75% 69.61% 66.83% 70.00% 258.42% 77.24% 0.00% 205,900.00% 981.63% 2,321.30%
Intangible Assets out of Total Assets
0.04 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
6.14% 0.79% 6.42% 13.07% 46.40% 17.31% 0.00% 43,433.33% 84.77% 159.15%
Graham Net Nets
0.19 0.04 0.01 0.07 1.32 0.58 — 1.34 0.62 2.01
Graham Number
0.87 1.91 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Earnings Yield
0.71% 1.16% (12.78%) (44.04%) (315.23%) (44.83%) — (33.57%) (65.38%) (218.29%)
Free Cash Flow Yield
(0.14%) (0.62%) 1.15% 1.01% (303.37%) (45.69%) — (32.68%) (40.55%) (212.07%)
Revenue per Share
1.30 1.24 1.72 1.61 3.59 16.38 0.00 0.01 4.46 7.67
Operating CF per Share
0.01 (0.04) 0.39 0.17 (40.98) (43.03) (54.47) (38.17) (87.30) (355.23)
Capex per Share
(0.02) (0.03) (0.12) (0.08) (0.41) (0.21) (0.08) (0.50) (0.10) 40.31
Free Cash Flow per Share
(0.01) (0.07) 0.27 0.09 (41.39) (43.24) (54.55) (38.68) (87.40) (314.92)
Cash per Share
0.59 0.31 0.51 0.40 22.92 62.03 96.00 160.66 165.39 702.54
Shareholders Equity per Share
1.59 1.16 1.19 1.14 20.10 59.47 85.35 160.35 134.74 309.06
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.59 1.16 1.19 1.14 20.10 59.47 85.35 160.35 134.74 309.06
Free Cash Flow
(0.88) (6.37) 17.97 5.68 (84.59) (55.31) (43.68) (28.93) (19.96) (16.38)
Working Capital
84.08 45.27 37.17 37.41 37.31 71.71 67.17 119.19 30.37 15.56
Capital Expenditures
(1.89) (2.73) (7.92) (5.00) (0.84) (0.27) (0.06) (0.38) (0.02) 2.10
Net Current Asset Value
78.52 37.78 19.16 37.12 36.90 70.73 65.85 119.02 30.37 15.50
EV/EBIT
47.30 62.38 0.00 58.98 0.16 0.00 — 0.78 0.00 0.45
Capex to Sales
0.02 0.03 0.07 0.05 0.11 0.01 0.00 62.67 0.02 (5.25)
Price to Operating Income
54.91 63.70 0.00 61.15 0.00 0.00 — 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.11 0.07 0.05 0.06 0.30 0.32 0.48 0.39 0.63 0.88
Cash ROIC
(0.45%) (5.09%) 16.05% 5.83% (96.20%) (35.59%) (30.08%) (12.05%) (27.11%) (22.74%)
Accounts Receivable Turnover
4.16 5.13 6.76 10.79 2.86 2.29 0.00 0.00 0.00 1.53
Accounts Payable Turnover
46.69 16.78 19.44 1.47 1.20 1.79 0.05 0.00 0.00 0.00
Inventory Turnover
0.66 0.73 0.89 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
8.36 10.15 27.95 9.29 317.47 236.26 10,697.50 0.00 0.00 0.00
Days of Inventory on Hand
685.45 595.52 337.05 466.21 0.00 0.00 0.00 — — —
Average Receivables
28.04 20.62 16.79 9.48 2.57 9.16 7.52 — — 0.26
Average Payables
0.12 0.23 0.24 3.27 6.18 5.11 2.76 1.00 0.79 0.89
Average Inventory
8.25 5.31 5.20 — — — — — — —
Average Assets
145.77 120.97 100.65 70.21 75.25 96.70 111.74 82.22 38.80 53.81
Average Common Equity
120.34 56.18 43.08 56.65 58.58 72.20 94.14 75.36 23.42 23.75

Fold the line items

Columns are period end dates